TECHNESCAN HIDA Drug Patent Profile

When do Technescan Hida patents expire, and when can generic versions of Technescan Hida launch?

Technescan Hida is a drug marketed by Draximage and is included in one NDA.

The generic ingredient in TECHNESCAN HIDA is technetium tc-99m lidofenin kit. There are four drug master file entries for this compound. Additional details are available on the technetium tc-99m lidofenin kit profile page.

Summary for TECHNESCAN HIDA

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	2
Patent Applications:	72
DailyMed Link:	TECHNESCAN HIDA at DailyMed

US Patents and Regulatory Information for TECHNESCAN HIDA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Draximage	TECHNESCAN HIDA	technetium tc-99m lidofenin kit	INJECTABLE;INJECTION	018489-001	Oct 31, 1986		DISCN	No	No

Expired US Patents for TECHNESCAN HIDA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Draximage	TECHNESCAN HIDA	technetium tc-99m lidofenin kit	INJECTABLE;INJECTION	018489-001	Oct 31, 1986

International Patents for TECHNESCAN HIDA

See the table below for patents covering TECHNESCAN HIDA around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	2612698
Belgium	840556
Canada	1070695	PRODUIT PHARMACEUTIQUE A BASE D'ACIDE IMINODIACETIQUE (IMINODIACETIC ACID PHARMACEUTICAL)
Australia	1189776
Canada	1096399	ACIDE IMINODIACETIQUE A USAGE PHARCACOLOGIQUE (IMINODIACETIC ACID PHARMACEUTICAL)
France	2322586
Japan	S5233631	RADIOACTIVE MEDICAL CHELATE COMPOUNDS AND PROCESS FOR TAKING PICTURES OUTSIDE

Supplementary Protection Certificates for TECHNESCAN HIDA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1178838	300736	Netherlands		PRODUCT NAME: TILMANOCEPT, DESGEWENST GELABELD MET TECHNETIUM TC 99M; REGISTRATION NO/DATE: EU/1/14/955 20141119

TECHNESCAN HIDA Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Technescan HIDA

Introduction

Technescan HIDA, a radiopharmaceutical used in hepatobiliary iminodiacetic acid (HIDA) scans, is a crucial diagnostic tool for evaluating the liver, gallbladder, and bile ducts. This article delves into the market dynamics and financial trajectory of Technescan HIDA, highlighting key drivers, challenges, and future projections.

Increasing Prevalence of Liver and Gallbladder Diseases

The demand for Technescan HIDA is significantly driven by the rising prevalence of liver and gallbladder diseases globally. Conditions such as infections, tumors, and functional abnormalities are becoming more common, necessitating accurate and non-invasive diagnostic tools like HIDA scans[1].

Technological Advancements

Continuous technological advancements in medical imaging play a pivotal role in the market dynamics of Technescan HIDA. Improvements in imaging resolution, diagnostic accuracy, and patient comfort enhance the appeal of HIDA scans. The integration of advanced technologies like single-photon emission computed tomography (SPECT) and hybrid imaging modalities further expands the diagnostic capabilities of HIDA scans, attracting more healthcare providers and broadening the scope of applications[1].

Government Initiatives and Healthcare Infrastructure

Government initiatives to improve healthcare access and affordability, along with increased awareness of liver diseases, contribute to the adoption of HIDA scans. The growing importance of preventive healthcare also drives the demand for early and accurate diagnosis, boosting the market for Technescan HIDA. Favorable reimbursement policies and regulatory frameworks facilitate easier access to these diagnostic procedures[1].

Competitive Landscape

The competitive landscape of the HIDA scan market is dynamic, with companies investing heavily in research and development to introduce new and improved imaging agents, equipment, and software. Strategic collaborations with healthcare institutions, distributors, and technology providers help market players expand their reach and enhance their market presence. Price competition, service quality, and customer support are also critical factors in this competitive environment[1].

Economic Factors

Global economic factors, such as fluctuations in currency exchange rates and healthcare spending patterns, add complexity to the market dynamics. Economic downturns can impact healthcare budgets, affecting the adoption rates of diagnostic procedures. However, the increasing awareness of liver diseases and the importance of early detection often outweigh economic challenges, ensuring sustained demand for Technescan HIDA[1].

Demographic Trends

Demographic trends, particularly the aging population in developed regions, contribute to the rising incidence of liver-related disorders. Lifestyle changes, including dietary habits and alcohol consumption, also influence the prevalence of liver diseases, thereby driving the demand for HIDA scans[1].

Market Size and Growth Projections

The global HIDA scan market, which includes Technescan HIDA, was valued at USD 0.2 billion in 2023 and is projected to grow to USD 0.8 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.43% during the forecast period (2024-2032)[1].

Regional Market Dynamics

• Europe: Europe holds the second-largest market share in the HIDA scan market. Countries like Germany, France, and the UK are major contributors due to increasing demand for technologically advanced devices and overall growth in the healthcare sector[1].
• Asia Pacific: The Asia Pacific region is the fastest-growing market, driven by improving healthcare infrastructure, a large patient population, and rising awareness about gallbladder treatment. India is expected to be the fastest-growing market in this region[1].

Financial Performance of Key Players

Companies like Lantheus, which produce radiopharmaceuticals including those used in HIDA scans, have shown significant financial performance. For instance, Lantheus reported strong revenue growth and Adjusted EBITDA improvements, reflecting their efforts in expanding the appropriate use of contrast agents and improving operating efficiency[2][5].

Challenges in Radiopharmaceutical Procurement

The cost of radiopharmaceuticals, including those used in HIDA scans, can be volatile due to factors like the conversion from highly-enriched uranium to other sources and regulatory compliance. These changes can lead to significant cost increases and supply chain disruptions, affecting the overall financial trajectory of the market[4].

Impact of Regulatory Changes

Regulatory changes, such as those mandated by the FDA regarding radiopharmaceutical preparation and compounding, can add to the costs and complexity of maintaining compliance. These regulations, while essential for safety and efficacy, can impact the financial performance of companies involved in the production and distribution of Technescan HIDA[4].

Reimbursement and Cost Management

Effective reimbursement models are crucial for managing the costs associated with radiopharmaceuticals. A bundled payment system, while effective in controlling costs, can present challenges if the cost of the radiopharmaceutical becomes the dominant part of the total procedure cost. This could force healthcare organizations to either bear the full burden of market price increases or opt for less efficacious diagnostic tests[4].

Key Takeaways

• The market for Technescan HIDA is driven by increasing prevalence of liver and gallbladder diseases and technological advancements.
• Government initiatives and healthcare infrastructure development are critical factors.
• The competitive landscape is characterized by product innovation and strategic collaborations.
• Economic and demographic trends influence market dynamics.
• The market is projected to grow significantly, with the Asia Pacific region being the fastest-growing.
• Regulatory changes and cost management strategies are essential for navigating market challenges.

FAQs

What are the primary drivers of the Technescan HIDA market?

The primary drivers include the increasing prevalence of liver and gallbladder diseases, technological advancements in medical imaging, and government initiatives to improve healthcare access and affordability.

How do technological advancements impact the Technescan HIDA market?

Technological advancements improve imaging resolution, diagnostic accuracy, and patient comfort, and the integration of advanced technologies like SPECT and hybrid imaging modalities expands diagnostic capabilities.

What role do government initiatives play in the market?

Government initiatives to improve healthcare access and affordability, along with increased awareness of liver diseases, contribute to the adoption of HIDA scans.

How does the competitive landscape influence the market?

The competitive landscape is dynamic, with companies investing in research and development, strategic collaborations, and competing on price, service quality, and customer support.

What are the projected growth rates for the HIDA scan market?

The global HIDA scan market is projected to grow from USD 0.3 billion in 2024 to USD 0.8 billion by 2032, exhibiting a CAGR of 6.43% during the forecast period.

How do economic factors affect the market?

Economic factors such as fluctuations in currency exchange rates and healthcare spending patterns can impact healthcare budgets, but the demand for HIDA scans remains robust due to the importance of early detection of liver diseases.

What are the key regional markets for Technescan HIDA?

Europe holds the second-largest market share, while the Asia Pacific region is the fastest-growing market, driven by improving healthcare infrastructure and rising awareness.

How do regulatory changes impact the market?

Regulatory changes, such as those related to radiopharmaceutical preparation and compounding, can increase costs and complexity, affecting the financial performance of companies involved.

What is the importance of reimbursement models in the market?

Effective reimbursement models are crucial for managing the costs associated with radiopharmaceuticals, ensuring that healthcare organizations can maintain access to these diagnostic tools without significant financial strain.

Sources

1. Market Research Future: HIDA Scan Market Analysis | Market Research Future
2. Lantheus Holdings: First quarter Adjusted EBITDA increases 29% to $20.6 million
3. Avalere: How May the IRA Shift Part D Market Dynamics?
4. Vizient, Inc.: Can the SPECT nuclear imaging modality be sustained?
5. Lantheus MI Holdings, Inc.: Adjusted EBITDA as presented in “Prospectus Summary—Summary Consolidated. Financial and Other Data”